NCT05412459View on ClinicalTrials.gov

99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy

CompletedOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

January 31, 2023

Conditions
HER2-positive Breast CancerFemale
Interventions
DRUG

99mTc-DARPinG3

Diagnostic test (99mTc-DARPinG3-based SPECT) is used for the assessment of the effect of anticancer therapy.

Trial Locations (2)

Unknown

Tomsk NRMC, Tomsk

TomskNRMC, Tomsk

All Listed Sponsors
collaborator

Uppsala University

OTHER

lead

Tomsk National Research Medical Center of the Russian Academy of Sciences

OTHER